(Total Views: 198)
Posted On: 12/13/2021 2:32:16 PM
Post# of 25471
$HALB Halberd Successfully Eradicates Interleukin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases
https://www.accesswire.com/677159/halberd-suc...e-diseases
JACKSON CENTER, PA / ACCESSWIRE / December 13, 2021 / Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-1 is associated with numerous diseases ranging from autoimmune to Multiple Sclerosis and Alzheimer's Disease. Halberd's demonstrated ability to control the levels of IL-1, coupled with its previous successful elimination of TNF-alpha and other inflammatory cytokines and antigens from CSF, the company believes it has achieved unparalleled progress toward slowing or preventing the onset of Alzheimer's Disease and other disease states.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board certified attending neurologist remarked, "Interleukin-1 is associated with many diseases, including critically life-threatening and quality of life deterioration afflictions. The ability to control the levels of IL-1 in cerebral spinal fluid gives us an effective tool in obstructing the progression of various neurological diseases, especially Alzheimer's, as well as other diseases with the same antigens and/or cytokines."
William A. Hartman, Halberd Corporation's Chairman, President & CEO, added, "We have now demonstrated that through our patented and patent pending extracorporeal laser irradiation methodology that we can eradicate targeted disease antigens and inflammatory cytokines associated with neurodegenerative diseases. We have no doubt that our technology will also be successful in eliminating the balance of the inflammatory cytokines and excitatory neurotransmitters identified in our test plan.
Hartman continued, "Our longer-term objective continues to focus on the eradication of the remaining pathogens from CSF and blood related to Alzheimer's Disease, Parkinson's Disease, Lou Gehrig's Disease, Epilepsy and Obesity. Halberd's advancement in the elimination of the pathogens listed above is unique in the industry. Our goal is to create a revolution in the successful treatment of the causes of neurodegenerative diseases that heretofore have not been adequately treated."
https://www.accesswire.com/677159/halberd-suc...e-diseases
JACKSON CENTER, PA / ACCESSWIRE / December 13, 2021 / Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-1 is associated with numerous diseases ranging from autoimmune to Multiple Sclerosis and Alzheimer's Disease. Halberd's demonstrated ability to control the levels of IL-1, coupled with its previous successful elimination of TNF-alpha and other inflammatory cytokines and antigens from CSF, the company believes it has achieved unparalleled progress toward slowing or preventing the onset of Alzheimer's Disease and other disease states.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board certified attending neurologist remarked, "Interleukin-1 is associated with many diseases, including critically life-threatening and quality of life deterioration afflictions. The ability to control the levels of IL-1 in cerebral spinal fluid gives us an effective tool in obstructing the progression of various neurological diseases, especially Alzheimer's, as well as other diseases with the same antigens and/or cytokines."
William A. Hartman, Halberd Corporation's Chairman, President & CEO, added, "We have now demonstrated that through our patented and patent pending extracorporeal laser irradiation methodology that we can eradicate targeted disease antigens and inflammatory cytokines associated with neurodegenerative diseases. We have no doubt that our technology will also be successful in eliminating the balance of the inflammatory cytokines and excitatory neurotransmitters identified in our test plan.
Hartman continued, "Our longer-term objective continues to focus on the eradication of the remaining pathogens from CSF and blood related to Alzheimer's Disease, Parkinson's Disease, Lou Gehrig's Disease, Epilepsy and Obesity. Halberd's advancement in the elimination of the pathogens listed above is unique in the industry. Our goal is to create a revolution in the successful treatment of the causes of neurodegenerative diseases that heretofore have not been adequately treated."
(0)
(0)
